ETFs
I
INCY
Incyte Corp
97.82
+2.50+2.62%After Hours: 97.90 +0.08 +0.08%19:52 04/17 EDT
OPEN/PREV CLOSE96.60/95.32
TODAY RANGE95.63-97.94
VOL1.53M
MARKET CAP19.47B
52 WEEK RANGE56.13-112.29
AVG VOL (3M)1.70M
% TURNOVER0.77%
TURNOVER--
P/E (TTM)15.26
% RANGE2.38%
EPS(TTM)6.41
P/E(FORWARD)15.93
P/B3.757
BVPS26.04
DIVIDEND--
P/S3.776
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP19.07B
SHARES OUTSTANDING199.01M
NEXT EARNINGS04/27-05/01
FREE FLOAT194.97M
LOT SIZE1
EX-DATE09/01/2000
News
Press Releases
Financial Reports
Profile
Simply Wall St·1d ago
Is It Too Late To Consider Incyte (INCY) After Its 63.8% One Year Rally?
PUBT·2d ago
Prime Medicine names Svetlana Makhni as CFO
Simply Wall St·3d ago
Assessing Incyte (INCY) Valuation After New Adagene Collaboration In Colorectal Cancer
Seeking Alpha·5d ago
Stock index futures advance on hopes of U.S.-Iran peace talks
Simply Wall St·6d ago
New Adagene Immuno‑Oncology Tie‑Up Could Be A Game Changer For Incyte (INCY)
NASDAQ·04/09 20:40
Incyte Now #415 Largest Company, Surpassing Textron
Dow Jones·04/09 12:02
Press Release: Incyte to Report First Quarter Financial Results
Reuters·04/09 12:00
Incyte schedules first-quarter results conference call and webcast
TipRanks·04/07 15:11
Incyte price target raised to $95 from $92 at RBC Capital
Reuters·04/07 11:33
Palvella Therapeutics names Kent Taylor senior vice president of sales
Reuters·04/07 10:24
INCYTE <INCY.O>: RBC RAISES TARGET PRICE TO $95 FROM $92
Same Industry
Name/Symbol
Change%
Price